156 related articles for article (PubMed ID: 7584913)
21. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers.
Delacrétaz E; Nussberger J; Biollaz J; Waeber B; Brunner HR
Hypertension; 1995 Jan; 25(1):14-21. PubMed ID: 7843746
[TBL] [Abstract][Full Text] [Related]
22. Effects of YM358, an angiotensin II type 1 (AT1) receptor antagonist, and enalapril on blood pressure and vasoconstriction in two renal hypertension models.
Tokioka T; Shibasaki M; Fujimori A; Matsuda-Satoh Y; Uchida W; Inagaki O; Yanagisawa I
Biol Pharm Bull; 2000 Feb; 23(2):174-81. PubMed ID: 10706380
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 1st communication: antihypertensive effects of valsartan in hypertensive models.
Yamamoto S; Hayashi N; Kometani M; Nakao K; Inukai T
Arzneimittelforschung; 1997 May; 47(5):604-12. PubMed ID: 9205773
[TBL] [Abstract][Full Text] [Related]
24. Effects of candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats.
Noda M; Fukuda R; Matsuo T; Ohta M; Nagano H; Imura Y; Nishikawa K; Shibouta Y
Kidney Int Suppl; 1997 Dec; 63():S136-9. PubMed ID: 9407442
[TBL] [Abstract][Full Text] [Related]
25. Acute renal effects of AT1-receptor blockade after exogenous angiotensin II infusion in healthy subjects.
Schmitt F; Martinez F; Brillet G; Nguyen-Khoa T; Brouard R; Sissmann J; Lacour B; Grunfeld JP
J Cardiovasc Pharmacol; 1998 Feb; 31(2):314-21. PubMed ID: 9475275
[TBL] [Abstract][Full Text] [Related]
26. Role of angiotensin II in cerebrovascular and renal damage in deoxycorticosterone acetate-salt hypertensive rats.
Wada T; Kanagawa R; Ishimura Y; Inada Y; Nishikawa K
J Hypertens; 1995 Jan; 13(1):113-22. PubMed ID: 7759841
[TBL] [Abstract][Full Text] [Related]
27. Additive effects of losartan and enalapril on blood pressure and plasma active renin.
Azizi M; Guyene TT; Chatellier G; Wargon M; Ménard J
Hypertension; 1997 Feb; 29(2):634-40. PubMed ID: 9040450
[TBL] [Abstract][Full Text] [Related]
28. Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (+-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats.
Inada Y; Wada T; Shibouta Y; Ojima M; Sanada T; Ohtsuki K; Itoh K; Kubo K; Kohara Y; Naka T
J Pharmacol Exp Ther; 1994 Mar; 268(3):1540-7. PubMed ID: 8138966
[TBL] [Abstract][Full Text] [Related]
29. Combined effects of the angiotensin II antagonist candesartan cilexetil (TCV-116) and other classes of antihypertensive drugs in spontaneously hypertensive rats.
Wada T; Sanada T; Ojima M; Kanagawa R; Nishikawa K; Inada Y
Hypertens Res; 1996 Dec; 19(4):247-54. PubMed ID: 8986455
[TBL] [Abstract][Full Text] [Related]
30. Effects of the new angiotensin II type 1 receptor antagonist KRH-594 on several types of experimental hypertension.
Inada Y; Murakami M; Kaido K; Nakao K
Arzneimittelforschung; 1999 Jan; 49(1):13-21. PubMed ID: 10028373
[TBL] [Abstract][Full Text] [Related]
31. Effects of TCV-116 on endothelin-1 and PDGF A-chain expression in angiotensin II-induced hypertensive rats.
Hara K; Kobayashi N; Nakano S; Mori Y; Tsubokou Y; Matsuoka H
Hypertens Res; 2001 Jan; 24(1):55-64. PubMed ID: 11213031
[TBL] [Abstract][Full Text] [Related]
32. Effects of acute AT1 receptor blockade by candesartan on arterial pressure and renal function in rats.
Cervenka L; Wang CT; Navar LG
Am J Physiol; 1998 May; 274(5):F940-5. PubMed ID: 9612332
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological profile of a novel nonpeptide angiotensin II subtype 1 receptor antagonist, TCV-116.
Nishikawa K; Inada Y; Shibouta Y; Wada T; Ojima M; Kubo K; Naka T
Blood Press Suppl; 1994; 5():7-14. PubMed ID: 7889205
[TBL] [Abstract][Full Text] [Related]
34. Influence of irbesartan and enalapril on changes of renal function associated with the established phase of l-NAME hypertension.
Jover B; Herizi A; Casellas D; Mimran A
J Hypertens; 2001 Nov; 19(11):2039-46. PubMed ID: 11677370
[TBL] [Abstract][Full Text] [Related]
35. Effect of an angiotensin II receptor antagonist, TCV-116, on cardiac hypertrophy and coronary circulation in spontaneously hypertensive rats.
Takeda K; Fujita H; Nakamura K; Uchida A; Tanaka M; Itoh H; Nakata T; Sasaki S; Nakagawa M
Blood Press Suppl; 1994; 5():94-8. PubMed ID: 7889211
[TBL] [Abstract][Full Text] [Related]
36. The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin.
Perico N; Remuzzi A; Sangalli F; Azzollini N; Mister M; Ruggenenti P; Remuzzi G
J Am Soc Nephrol; 1998 Dec; 9(12):2308-17. PubMed ID: 9848785
[TBL] [Abstract][Full Text] [Related]
37. Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients.
Pechère-Bertschi A; Nussberger J; Decosterd L; Armagnac C; Sissmann J; Bouroudian M; Brunner HR; Burnier M
J Hypertens; 1998 Mar; 16(3):385-93. PubMed ID: 9557932
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological and pharmacokinetic evaluation of EXP3312, an orally-active non-peptide angiotensin II-receptor antagonist.
Wong YN; Wong PC
J Pharm Pharmacol; 1996 May; 48(5):492-7. PubMed ID: 8799873
[TBL] [Abstract][Full Text] [Related]
39. A comparison of the hypotensive and hypoglycaemic actions of an angiotensin converting enzyme inhibitor, an AT1a antagonist and troglitazone.
Chen S; Noguchi Y; Izumida T; Tatebe J; Katayama S
J Hypertens; 1996 Nov; 14(11):1325-30. PubMed ID: 8934361
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models.
Lacour C; Canals F; Galindo G; Cazaubon C; Segondy D; Nisato D
Eur J Pharmacol; 1994 Nov; 264(3):307-16. PubMed ID: 7698170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
